Press Releases

May 10, 2013
      TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES     1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii GW Pharmaceuticals PLC 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of
May 09, 2013
  London, UK, 9 May 2013: GW Pharmaceuticals (NASDAQ:GWPH, AIM: GWP, "GW" or the "Company") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, in conformity with 5.6.1 of the Disclosure and
Apr 12, 2013
Porton Down, UK, 12 April 2013: GW Pharmaceuticals plc (AIM: GWP or the “Company”) hereby provides notification that, at the General Meeting of Company held earlier today, all the resolutions set out in the Notice of General Meeting sent to shareholders on 22 March 2013 were duly passed without
Apr 03, 2013
Porton Down, UK; 3 April 2013: GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the United States Patent and Trademark Office (USPTO) has
Mar 19, 2013
Update on Sativex® in Germany Porton Down, UK, 19 March 2013: GW Pharmaceuticals plc (AIM: GWP, “GW”), the specialty pharmaceutical company focused on cannabinoid science, today provides an update on pricing negotiations in Germany for Sativex® being conducted by GW’s licensing partner, Almirall